- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Kardigan auf Cantor-Konferenz: Plattformansatz für Herzmedikamente | 1 | Investing.com Deutsch | ||
| 17.08. | Citi agrees to acquire Kard Financial for commerce rewards | 3 | The Paypers | ||
| 14.08. | Citi to acquire US rewards tech company Kard Financial | 4 | FinTech Futures | ||
| KARDIGAN Aktie jetzt für 0€ handeln | |||||
| 14.08. | Citi To Acquire Kard To Supercharge Personalized Rewards And Commerce Media | 3 | pulse2.com | ||
| 14.08. | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | 735 | AFX News | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| 13.08. | Citi to acquire commerce rewards platform Kard Financial | 4 | Investing.com | ||
| 13.08. | Citigroup übernimmt Commerce-Prämienplattform Kard Financial | 3 | Investing.com Deutsch | ||
| 11.08. | Kardigan, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.08. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.07. | TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline | 2 | Investing.com | ||
| 13.07. | Kardigan: TD Cowen startet Coverage mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | JPMorgan initiates Kardigan stock with overweight on pipeline | 2 | Investing.com | ||
| 13.07. | Jefferies initiates Kardigan stock with buy rating on cardiology pipeline | 1 | Investing.com | ||
| 13.07. | JPMorgan startet Kardigan-Aktie mit "Overweight" - Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | Jefferies startet Kardigan mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 23.06. | How Kardigan spun deal leftovers into a $400M IPO | 1 | BioPharma Dive | ||
| 23.06. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.06. | Kardigan erzielt 460 Millionen US-Dollar bei Börsengang an der NASDAQ | 2 | Investing.com Deutsch | ||
| 22.06. | Kardigan closes $460 million IPO on Nasdaq | 1 | Investing.com | ||
| 22.06. | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 459 | Business Wire | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 3,680 | +0,55 % | EyePoint nach gemischten Studiendaten: Hoffnung ruht auf entscheidender Folgestudie | ||
| NEKTAR THERAPEUTICS | 59,90 | -0,47 % | Nektar Therapeutics Announces Second Quarter 2026 Financial Results | SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,688 | +2,84 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update | AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,440 | -2,27 % | Ironwood Pharmaceuticals auf Wells-Fargo-Konferenz: LINZESS-Comeback treibt Trendwende voran | ||
| GALECTIN THERAPEUTICS | 3,620 | +7,10 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,895 | -1,53 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System | HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completing orientation and training at Zeta Surgical's... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,240 | +0,90 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update | PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 11,180 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer | Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,080 | 0,00 % | InMed Pharmaceuticals: InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update | Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,278 | +2,43 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 2,500 | +5,04 % | Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented... ► Artikel lesen | |
| INVENTIVA | 3,435 | -6,40 % | INVENTIVA: Inventiva to Present Multiple Abstracts at Paris MASH 2026 | Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize... ► Artikel lesen | |
| MEDICINOVA | 1,805 | -0,28 % | MediciNova, Inc.: MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients | LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 0,980 | 0,00 % | Milestone Pharmaceuticals bei Wells Fargo: Erfolge bei der Markteinführung, größere Tests stehen bevor | ||
| ANBIO BIOTECHNOLOGY | 5,600 | +1,82 % | Anbio Biotechnology - 6-K, Report of foreign issuer |
KARDIGAN INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,080 (+0,43 %) liegt der Kurs bei 18,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KARDIGAN INC finden Sie auf Wallstreet Online.